Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates

Company Performance - Viridian Therapeutics reported a quarterly loss of $0.81 per share, which was better than the Zacks Consensus Estimate of a loss of$ 1.05, representing an earnings surprise of 22.86% [1] - The company posted revenues of $0.07 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 17.24%, with no change in revenue compared to the previous year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates two times and topped consensus revenue estimates just once [2] Stock Movement and Outlook - Viridian Therapeutics shares have declined approximately 19% since the beginning of the year, contrasting with the S&P 500's gain of 1.3% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is -$ 0.98 on revenues of $0.15 million, and for the current fiscal year, it is -$ 4.31 on revenues of $0.55 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Viridian Therapeutics belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]